Dimethyl fumarate use as the first choice in a woman with relapsing-remitting type of multiple sclerosis in childbearing age – case report Case report

Abstract

Relapsing-remitting type of multiple sclerosis often occurs in young women in childbearing age. That is why immunomodulating treatment preventing the progression of disease that enables conception without suspending the treatment before it, is beneficial especially for this group of patients. We present a case of a young woman that is treated with dimethyl fumarate since 2018. Then, at the age of 20, after diagnosis of relapsing-remitting multiple sclerosis, the treatment with dimethyl fumarate was introduced. After about 1.5 year of therapy the patient got pregnant and the treatment was suspended. She bore two healthy children with interruption in dimethyl fumarate treatment. After the second delivery she had a relapse of disease. Because of breastfeeding, bridging therapy with glatiramer acetate was used. At present, the treatment is being switched to dimethyl fumarate again. This treatment enabled the patient delivery of two children without interruption in the treatment before pregnancy.